Eric bouteiller (37 risultati)

Condizione: good. Befriedigend/Good: Durchschnittlich erhaltenes Buch bzw. Schutzumschlag mit Gebrauchsspuren, aber vollständigen Seiten. / Describes the average WORN book or dust jacket that has all the pages present.

Softcover. Condizione: Très bon. Ancien livre de bibliothèque avec équipements. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Ammareal gives back up to 15% of this item's net price to charity organizations.…

Softcover. Condizione: Très bon. Ancien livre de bibliothèque avec équipements. Edition 2013. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 2013. Ammareal gives back up to 15% of this item's net price to charity organizations. …

Condizione: Neuf.

in-8° pp. 64, bross. edit. Ottimo stato.

Paris, Calmann Levy 1997. In-8 broché de 329 pages. Quelques passages soulignés sinon bon état.

Condizione: Neuf.

Condizione: New.

HRD. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Condizione: New. Brand new book, sourced directly from publisher. Dispatch time is 24-48 hours from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely.

Condizione: As New. Unread book in perfect condition.

Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Hardback. Condizione: New. 'Because at the heart of the apparent conflict between public health concerns and capitalistic interests, market access for pharmaceuticals is largely driven by political considerations, the difference with usual consumer goods being that pharmaceuticals are saving lives or years of life in good health'. Pharmaceuticals are mainly sourced by companies investing in costly RandD and production at their own risks to make them globally available. However, access for patients in need can be restricted due to insufficient medical resources and/or unaffordability. The dilemma between rewarding innovation with prices in line with value and risks for companies and ensuring affordability for patients or health insurances has become critical for all stakeholders, with political and economic implications. The development of universal health coverage puts pressure on governments to control directly or indirectly reimbursement and prices of pharmaceuticals, whereas the flow of innovations addressing infectious, chronic, and life-threatening diseases, thanks to accelerated scientific progress, is growing constantly.Management of pharmaceutical health care expenditure approach varies according to the historical, cultural, and economic backgrounds that contribute to building each health care system, and companies are confronted with a very complex environment to launch their new drugs and manage their lifecycle until loss of patent. This book explores the different models of health care systems (e.g., Europe, United States, Japan, China) and the criteria and processes for decision making in coverage and pricing of pharmaceuticals. It also provides the analytic tools that are used to inform the decisions, and how market access strategy can be integrated in the product life cycle. Short case studies related to specific disease areas or methods are supporting exposed concepts and methods.This book targets primarily students, but may prove useful to industry or insurance executives and eventually public decision makers with interest in the field: all will find relevant insights and sources to dig deeper into the topic. The content has been developed partially through a well received teaching program at CEIBS MBA since 2020.…

Condizione: New.

Hardcover. Condizione: new. Hardcover. This book addresses the global pharmaceutical dilemma through balancing innovation and accessibility and providing a comprehensive toolbox with key concepts and methods for all stakeholders.Pharmaceuticals are an essential part of health care, and mainly sourced by companies investing in costly R&D and production at their own risks to make them globally available. However, access for patients in need can be restricted due to insufficient medical resources and/or unaffordability. The dilemma between rewarding innovation with prices in line with value and risks for companies and ensuring affordability for patients or health insurances has become critical for all stakeholders, with political and economic implications. The development of universal health coverage puts pressure on governments to control directly or indirectly reimbursement and prices of pharmaceuticals, whereas the flow of innovations addressing infectious, chronic, and life-threatening diseases, thanks to accelerated scientific progress, is growing constantly. Management of pharmaceutical health care expenditure approach varies according to the historical, cultural, and economic backgrounds that contribute to building each health care system, and companies are confronted with a very complex environment to launch their new drugs and manage their lifecycle until loss of patent. This book explores the different models of health care systems (e.g., Europe, United States, Japan, China) and the criteria and processes for decision making in coverage and pricing of pharmaceuticals. It also provides the analytic tools that are used to inform the decisions, and how market access strategy can be integrated in the product life cycle. Short case studies related to specific disease areas or methods are supporting exposed concepts and methods.This book targets students, industry or insurance stakeholders, and eventually public decision makers: all will find relevant insights and sources to dig deeper into the topic. The content has been developed partially through a teaching program at CEIBS MBA since 2020. This book provides a conceptual and pragmatic approach to the complexity of market access for pharmaceuticals across different types of economies and health care systems around the world, providing a comprehensive toolbox with key concepts and methods for students, executives from companies, public decision-makers and payers interested in the field. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Condizione: New.

Hardback. Condizione: New. 'Because at the heart of the apparent conflict between public health concerns and capitalistic interests, market access for pharmaceuticals is largely driven by political considerations, the difference with usual consumer goods being that pharmaceuticals are saving lives or years of life in good health'. Pharmaceuticals are mainly sourced by companies investing in costly RandD and production at their own risks to make them globally available. However, access for patients in need can be restricted due to insufficient medical resources and/or unaffordability. The dilemma between rewarding innovation with prices in line with value and risks for companies and ensuring affordability for patients or health insurances has become critical for all stakeholders, with political and economic implications. The development of universal health coverage puts pressure on governments to control directly or indirectly reimbursement and prices of pharmaceuticals, whereas the flow of innovations addressing infectious, chronic, and life-threatening diseases, thanks to accelerated scientific progress, is growing constantly.Management of pharmaceutical health care expenditure approach varies according to the historical, cultural, and economic backgrounds that contribute to building each health care system, and companies are confronted with a very complex environment to launch their new drugs and manage their lifecycle until loss of patent. This book explores the different models of health care systems (e.g., Europe, United States, Japan, China) and the criteria and processes for decision making in coverage and pricing of pharmaceuticals. It also provides the analytic tools that are used to inform the decisions, and how market access strategy can be integrated in the product life cycle. Short case studies related to specific disease areas or methods are supporting exposed concepts and methods.This book targets primarily students, but may prove useful to industry or insurance executives and eventually public decision makers with interest in the field: all will find relevant insights and sources to dig deeper into the topic. The content has been developed partially through a well received teaching program at CEIBS MBA since 2020.…

Couverture souple. Condizione: Bon. Bouteiller Eric - Les nouveaux empereurs. L'épopée du capitalisme chinois - 1997 - Broché 24 CM - 328 pages.

Condizione: New.

Condizione: New.

Condizione: New. 2024. hardcover. . . . . .

Condizione: New. In English.

Condizione: As New. Unread book in perfect condition.

Couverture souple. Condizione: bon. RO80256537: 1995. In-12. Broché. Bon état, Couv. convenable, Dos satisfaisant, Intérieur frais. 124 pages. . . . Classification Dewey : 950-Histoire générale de l'Asie.

Condizione: New. 2024. hardcover. . . . . . Books ship from the US and Ireland.

Condizione: NEW.

Condizione: Très bon. Merci, votre achat aide à financer des programmes de lutte contre l'illettrisme.

Hardback. Condizione: New. 'Because at the heart of the apparent conflict between public health concerns and capitalistic interests, market access for pharmaceuticals is largely driven by political considerations, the difference with usual consumer goods being that pharmaceuticals are saving lives or years of life in good health'. Pharmaceuticals are mainly sourced by companies investing in costly RandD and production at their own risks to make them globally available. However, access for patients in need can be restricted due to insufficient medical resources and/or unaffordability. The dilemma between rewarding innovation with prices in line with value and risks for companies and ensuring affordability for patients or health insurances has become critical for all stakeholders, with political and economic implications. The development of universal health coverage puts pressure on governments to control directly or indirectly reimbursement and prices of pharmaceuticals, whereas the flow of innovations addressing infectious, chronic, and life-threatening diseases, thanks to accelerated scientific progress, is growing constantly.Management of pharmaceutical health care expenditure approach varies according to the historical, cultural, and economic backgrounds that contribute to building each health care system, and companies are confronted with a very complex environment to launch their new drugs and manage their lifecycle until loss of patent. This book explores the different models of health care systems (e.g., Europe, United States, Japan, China) and the criteria and processes for decision making in coverage and pricing of pharmaceuticals. It also provides the analytic tools that are used to inform the decisions, and how market access strategy can be integrated in the product life cycle. Short case studies related to specific disease areas or methods are supporting exposed concepts and methods.This book targets primarily students, but may prove useful to industry or insurance executives and eventually public decision makers with interest in the field: all will find relevant insights and sources to dig deeper into the topic. The content has been developed partially through a well received teaching program at CEIBS MBA since 2020.…